Proficio Capital Partners LLC Grows Stake in AstraZeneca PLC (NASDAQ:AZN)

Proficio Capital Partners LLC boosted its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 92.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,773 shares of the company's stock after buying an additional 9,967 shares during the period. Proficio Capital Partners LLC's holdings in AstraZeneca were worth $1,527,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of AZN. Banque Transatlantique SA acquired a new stake in shares of AstraZeneca during the fourth quarter worth about $26,000. Confluence Investment Management LLC purchased a new stake in shares of AstraZeneca during the 1st quarter valued at $27,000. Larson Financial Group LLC boosted its position in AstraZeneca by 297.9% in the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company's stock valued at $28,000 after buying an additional 289 shares during the last quarter. Mascagni Wealth Management Inc. bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $29,000. Finally, FNY Investment Advisers LLC acquired a new position in AstraZeneca in the 1st quarter worth approximately $29,000. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Price Performance

Shares of AstraZeneca stock traded up $1.43 on Tuesday, reaching $70.15. The company's stock had a trading volume of 1,657,724 shares, compared to its average volume of 5,234,986. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The company has a market capitalization of $217.57 billion, a P/E ratio of 28.16, a PEG ratio of 1.26 and a beta of 0.37. The stock has a 50-day moving average price of $70.78 and a 200-day moving average price of $70.99.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.06 EPS. Analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on AZN. BNP Paribas initiated coverage on AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target for the company. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday, July 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $89.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.